Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* has type 2 diabetes mellitus~* is male, a female who cannot have children, or a female who agrees to use birth control during the study~* is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \[A1C\] 7.5-11.0%) or on oral single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)~Exclusion Criteria:~* Patient has type 1 diabetes mellitus or ketoacidosis~* Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)~* Patient is on a weight loss program not in the maintenance phase or on a weight loss medication~* Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer~* Patient is HIV positive~* Patient is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 50 mg + metformin 500 mg (Type: EXPERIMENTAL): Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
- Sitagliptin 50 mg + metformin 850 mg (Type: EXPERIMENTAL): Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
- Metformin 500 mg (Type: ACTIVE_COMPARATOR): Metformin 500 mg twice daily for 24 weeks.
- Metformin 850 mg (Type: ACTIVE_COMPARATOR): Metformin 850 mg twice daily for 24 weeks.
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Sitagliptin 100 mg once daily for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).